Gianfranco Calogiuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gianfranco Calogiuri has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alla Nakonechna
Chest and Allergy Clinic Imperial College Healthcare NHS Foundation Trust London UK
1 shared publication Annette Wagner
Department of Adult Allergy Guy's and St Thomas' NHS Foundation Trust London UK
1 shared publication- Annick Barbaud
Département de Dermatologie et Allergologie INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP, Sorbonne Université, Hôpital Tenon Paris France
1 shared publication - Aslı Gelincik
Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine Istanbul University Istanbul Türkiye
1 shared publication - Charlotte Gotthard Mortz
Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA) Odense University Hospital Odense Denmark
1 shared publication - Knut Brockow
Department of Dermatology and Allergy Biederstein, School of Medicine and Health Technical University of Munich Munich Germany
1 shared publication
Latest Publications
- Open Access
Hypersensitivity to Excipients in Drugs: An EAACI Position Paper
Drugs contain active pharmaceutical ingredients and excipients, compounds which enhance the pharmacokinetics, stability and palatability of the pharmaceutical formulation. While most drug hypersensitivity reactions (DHR) are caused by active ingredients, excipients may also be involved. Excipient‐related DHR are easily overlooked and may lead to repeated anaphylaxis in patients exposed to pharmaceutical formulations containing different active ingredients. We performed an extensive review of the literature to provide practical recommendations on when to suspect and how to diagnose and manage excipient hypersensitivity. Where literature was limited, the collective experience of the authors was taken into consideration. Excipient hypersensitivity should be suspected in patients with a history of anaphylaxis to multiple drugs with chemically unrelated active ingredients and specific drug classes such as oral laxatives and injectable depot steroids or progestogens. Polyethylene glycol, methylcelluloses, gelatine, povidone and mannitol were identified as the most common culprits of DHR. DHR evaluation should include review of the product monograph to ascertain the presence of possible culprit excipients. Specific diagnostic tests for excipients should be performed when appropriate, including skin, in vitro and provocation testing with pure excipients and drugs with and without the excipient as controls. We provide consensus‐based excipient‐specific recommendations on diagnostic testing based on best available evidence.
Open AccessHypersensitivity to Excipients in Drugs: An EAACI Position Paper
Drugs contain active pharmaceutical ingredients and excipients, compounds which enhance the pharmacokinetics, stability and palatability of the pharmaceutical formulation. While most drug hypersensitivity reactions (DHR) are caused by active ingredients, excipients may also be involved. Excipient‐related DHR are easily overlooked and may lead to repeated anaphylaxis in patients exposed to pharmaceutical formulations containing different active ingredients. We performed an extensive review of the literature to provide practical recommendations on when to suspect and how to diagnose and manage excipient hypersensitivity. Where literature was limited, the collective experience of the authors was taken into consideration. Excipient hypersensitivity should be suspected in patients with a history of anaphylaxis to multiple drugs with chemically unrelated active ingredients and specific drug classes such as oral laxatives and injectable depot steroids or progestogens. Polyethylene glycol, methylcelluloses, gelatine, povidone and mannitol were identified as the most common culprits of DHR. DHR evaluation should include review of the product monograph to ascertain the presence of possible culprit excipients. Specific diagnostic tests for excipients should be performed when appropriate, including skin, in vitro and provocation testing with pure excipients and drugs with and without the excipient as controls. We provide consensus‐based excipient‐specific recommendations on diagnostic testing based on best available evidence.